Category: GeoMx DSP

March 10, 2023 / Toxins

  • de Oliveira AK, Pramoonjago P, Rucavado A, Moskaluk C, Silva DT, Escalante T, Gutiérrez JM, Fox JW
Pathological and inflammatory events in muscle after the injection of snake venoms vary in different regions of the affected tissue and at different time intervals. In order to study such…
March 8, 2023 / Eur Urol

  • Hannan R, Mark F. McLaughlin, Laurentiu M. Pop, Ivan Pedrosa, Payal Kapur, Aurelie Garant, Chul Ahn, Alana Christie, James Zhu, Tao Wang, Liliana Robles, Deniz Durakoglugil, Solomon Woldu, Vitaly Margulis, Jeffrey Gahan, James Brugarolas, Robert Timmerman, Jeffrey Cadeddu
Background: Most renal cell carcinomas (RCCs) are localized and managed by active surveillance, surgery, or minimally invasive techniques. Stereotactic ablative radiation (SAbR) may provide an innovative non-invasive alternative although prospective…
March 3, 2023 / J Invest Dermatol

  • Chagani S, De Macedo MP, Carapeto F, Wang F, Marzese DM, Wani K, Haydu LE, Peng W, Ong GT, Warren SE, Beechem JM, Hoon DSB, Mills GB, Tetzlaff MT, Lazar AJ, Kwong LN, Davies MA
Loss of protein expression of the tumor suppressor PTEN is associated with increased cancer aggressiveness, decreased tumor immune infiltration, and resistance to immune and targeted therapies in melanoma. We assessed…
March 2, 2023 / Nat Rev Genet

  • Vandereyken K, Sifrim A, Thienpont B, Voet T
The joint analysis of the genome, epigenome, transcriptome, proteome and/or metabolome from single cells is transforming our understanding of cell biology in health and disease. In less than a decade,…
March 1, 2023 / Oncoimmunology

  • Valind A, Verhoeven BM, Enoksson J, Karlsson J, Christensson G, Mañas A, Aaltonen K, Jansson C, Bexell D, Baryawno N, Gisselsson D, Hagerling C
Despite aggressive treatment, the 5-year event-free survival rate for children with high-risk neuroblastoma is
February 28, 2023 / J Immunother Cancer

  • Song X, Xiong A, Wu F, Li X, Wang J, Jiang T, Chen P, Zhang X, Zhao Z, Liu H, Cheng L, Zhao C, Wang Z, Pan C, Cui X, Xu T, Luo H, Zhou C
Background: Immunotherapy for malignant tumors has made great progress, but many patients do not benefit from it. The complex intratumoral heterogeneity (ITH) hindered the in-depth exploration of immunotherapy. Conventional bulk…
February 27, 2023 / Transl Med Commun

  • Baranda JC, Mohyuddin GR, Bur AM, Shnayder Y, Sweeney KR, Kakarala K, Prouty M, Pathak H, Puri R, Mitra A, Madan R, Forrest ML, Huang A, Weir S, Godwin AK, Alhakamy NA, Griffin JD, Berkland CJ
Background: This window of opportunity trial evaluated the safety of intratumoral Copaxone® and profiled immune markers in biopsies before and after treatment. Methods: Patients with percutaneously accessible malignancies scheduled for…
February 23, 2023 / Transplantation

  • Zubair H, Azim S, Maluf DG, Mas VR, Martins PN
Solid organ transplantation saves thousands of lives suffering from end-stage diseases. Although early transplants experienced acute organ injury, medical breakthroughs, such as tissue typing, and use of immunosuppressive agents have…
February 21, 2023 / Front Oncol

  • Kazakova E, Rakina M, Sudarskikh T, Iamshchikov P, Tarasova A, Tashireva L, Afanasiev S, Dobrodeev A, Zhuikova L, Cherdyntseva N, Kzhyshkowska J, Larionova I
Introduction: Increasing evidence suggests that it is necessary to find effective and robust clinically validated prognostic biomarkers that can identify “high-risk” colorectal cancer (CRC) patients. Currently, available prognostic factors largely…
February 18, 2023 / Commun Biol

  • Xin J, Yang T, Wu X, Wu Y, Liu Y, Liu X, Jiang M, Gao W
Hepatic ischemia-reperfusion (I/R) injury is a common complication in liver transplantation. The connection between I/R-induced injury response and liver heterogeneity has yet to be fully understood. In this study, we…
February 16, 2023 / J Anat

  • Holst CB, Brochner CB, Vitting-Seerup K, Mollgard K
Outer radial glial cells (oRGs) give rise to neurons and glial cells and contribute to cell migration and expansion in developing neocortex. HOPX has been described as a marker of…
February 15, 2023 / Gut

  • Karamitopoulou E, Wenning AS, Acharjee A, Zlobec I, Aeschbacher P, Perren A, Gloor B
Objective: Most patients with pancreatic ductal adenocarcinoma (PDAC) will experience recurrence after resection. Here, we investigate spatially organised immune determinants of PDAC recurrence. Design: PDACs (n=284; discovery cohort) were classified…